ReviewFrontiers in molecular neuroscience2023
Therapeutic effects of phlorotannins in the treatment of neurodegenerative disorders.
Review in Frontiers in molecular neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- The Brown Algal Phlorotannin Dieckol Attenuates Amyloid-β Oligomer-Induced Oxidative DNA Damage and Senescence-like Stress in Human Neuron-like Cells.Marine drugs · 2026Article
- Ultrasonic-assisted extraction, purification, identification, and bioactivity evaluation of phlorotannins from Sargassum fusiforme: A comparative study of RSM and SVM-GA.Ultrasonics sonochemistry · 2026Article
- Review
- Neuroproteomic Profiling of the Anxiolytic Potential ofInternational journal of molecular sciences · 2026Article
- Neurological Benefits of Seaweed-Derived Compounds.Marine drugs · 2026Review
- Phlorotannins from Phaeophyceae: Structural Diversity, Multi-Target Bioactivity, Pharmacokinetic Barriers, and Nanodelivery System Innovation.Molecules (Basel, Switzerland) · 2025Review
- Therapeutic Potentials of the Seaweed-Derived Compounds for Alzheimer's Disease.Molecules (Basel, Switzerland) · 2025Review
- Are Algae a Good Source of Antioxidants? Mechanistic Insights into Antiradical Activity of Eckol.International journal of molecular sciences · 2025Article
- Marine Derived Strategies Against Neurodegeneration.Marine drugs · 2025Review
- Sustainable Recovery of Phlorotannins fromAntioxidants (Basel, Switzerland) · 2025Article
- Phlorotannin Supplement Improves Scopolamine-Induced Memory Dysfunction by Rescuing Synaptic Damage in Mice.Journal of microbiology and biotechnology · 2024Article
- A Pharmacokinetic and Bioavailability Study ofMarine drugs · 2024Article
- Optimization and Bioactive Evaluation ofAntioxidants (Basel, Switzerland) · 2024Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phlorotannins are natural polyphenolic compounds produced by brown marine algae and are currently found in nutritional supplements. Although they are known to cross the blood-brain barrier, their neuropharmacological actions remain unclear. Here we review the potential therapeutic benefits of phlorotannins in the treatment of neurodegenerative diseases. In mouse models of Alzheimer's disease, ethanol intoxication and fear stress, the phlorotannin monomer phloroglucinol and the compounds eckol, dieckol and phlorofucofuroeckol A have been shown to improve cognitive function. In a mouse model of Parkinson's disease, phloroglucinol treatment led to improved motor performance. Additional neurological benefits associated with phlorotannin intake have been demonstrated in stroke, sleep disorders, and pain response. These effects may stem from the inhibition of disease-inducing plaque synthesis and aggregation, suppression of microglial activation, modulation of pro-inflammatory signaling, reduction of glutamate-induced excitotoxicity, and scavenging of reactive oxygen species. Clinical trials of phlorotannins have not reported significant adverse effects, suggesting these compounds to be promising bioactive agents in the treatment of neurological diseases. We therefore propose a putative biophysical mechanism of phlorotannin action in addition to future directions for phlorotannin research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.